X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WOCKHARDT LTD. ALKEM LABORATORIES/
WOCKHARDT LTD.
 
P/E (TTM) x - -23.9 - View Chart
P/BV x 7.0 2.4 291.0% View Chart
Dividend Yield % 0.6 0.0 38,617.0%  

Financials

 ALKEM LABORATORIES   WOCKHARDT LTD.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
WOCKHARDT LTD.
Mar-18
ALKEM LABORATORIES/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,5891,012 157.0%   
Low Rs1,232532 231.8%   
Sales per share (Unadj.) Rs417.5355.9 117.3%  
Earnings per share (Unadj.) Rs56.3-60.3 -93.4%  
Cash flow per share (Unadj.) Rs64.7-46.8 -138.4%  
Dividends per share (Unadj.) Rs12.700.01 127,000.0%  
Dividend yield (eoy) %0.90 69,487.6%  
Book value per share (Unadj.) Rs292.9257.8 113.6%  
Shares outstanding (eoy) m119.57110.63 108.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.2 155.8%   
Avg P/E ratio x25.1-12.8 -195.7%  
P/CF ratio (eoy) x21.8-16.5 -132.1%  
Price / Book Value ratio x4.83.0 160.9%  
Dividend payout %22.60 -135,984.3%   
Avg Mkt Cap Rs m168,65385,379 197.5%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m9,1719,371 97.9%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m49,91539,369 126.8%  
Other income Rs m1,6451,202 136.8%   
Total revenues Rs m51,56140,571 127.1%   
Gross profit Rs m8,48218 46,351.4%  
Depreciation Rs m1,0061,495 67.3%   
Interest Rs m6712,555 26.2%   
Profit before tax Rs m8,451-2,830 -298.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,606257 624.9%   
Profit after tax Rs m6,731-6,669 -100.9%  
Gross profit margin %17.00 36,558.0%  
Effective tax rate %19.0-9.1 -209.2%   
Net profit margin %13.5-16.9 -79.6%  
BALANCE SHEET DATA
Current assets Rs m27,06233,796 80.1%   
Current liabilities Rs m15,32426,917 56.9%   
Net working cap to sales %23.517.5 134.6%  
Current ratio x1.81.3 140.7%  
Inventory Days Days6779 83.8%  
Debtors Days Days4189 46.3%  
Net fixed assets Rs m12,61039,664 31.8%   
Share capital Rs m239553 43.2%   
"Free" reserves Rs m34,49027,968 123.3%   
Net worth Rs m35,02728,522 122.8%   
Long term debt Rs m1,21221,731 5.6%   
Total assets Rs m54,38781,620 66.6%  
Interest coverage x13.6-0.1 -12,650.9%   
Debt to equity ratio x00.8 4.5%  
Sales to assets ratio x0.90.5 190.3%   
Return on assets %13.6-5.0 -270.0%  
Return on equity %19.2-23.4 -82.2%  
Return on capital %24.9-7.7 -323.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,5639,807 66.9%   
Fx outflow Rs m3,0121,789 168.4%   
Net fx Rs m3,5528,019 44.3%   
CASH FLOW
From Operations Rs m7,259684 1,060.6%  
From Investments Rs m1,8646,302 29.6%  
From Financial Activity Rs m-9,273-7,695 120.5%  
Net Cashflow Rs m-150-664 22.6%  

Share Holding

Indian Promoters % 66.9 74.5 89.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 2.3 1,439.1%  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 67,757 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (4QFY18); Net Profit Down 13.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, WOCKHARDT LTD. has posted a net profit of Rs 2 bn (down 13.4% YoY). Sales on the other hand came in at Rs 10 bn (up 17.9% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS